Aluminum hydroxide

Identification

Name
Aluminum hydroxide
Accession Number
DB06723
Type
Small Molecule
Groups
Approved, Investigational
Description

Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.

Structure
Thumb
Synonyms
  • Aluminium hydroxide
  • Aluminium hydroxide gel, dried
  • Aluminium hydroxide, dried
  • Aluminum hydroxide gel, dried
  • Aluminum hydroxide, dried
  • Dried aluminium hydroxide
  • Dried aluminum hydroxide gel
External IDs
NSC-664400
Product Ingredients
IngredientUNIICASInChI Key
Algeldrate03J11K103C1330-44-5SMYKVLBUSSNXMV-UHFFFAOYSA-K
Almagate568Z59H7ZJ66827-12-1MTEOMEWVDVPTNN-UHFFFAOYSA-E
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alu-tab Tab 600mgTablet600 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312001-08-01Canada
Aluminum HydroxideGel320 mg/5mLOralLLC Federal Solutions2013-08-12Not applicableUs
Aluminum HydroxideLiquid320 mg/5mLOralAtlantic Biologicals Corps.2005-02-01Not applicableUs
Aluminum HydroxideLiquid320 mg/5mLOralRugby2005-02-01Not applicableUs
Derma GranOintment.275 g/100gTopicalMckesson Medical Surgical2013-11-12Not applicableUs
Derma GranOintment.275 g/100gTopicalDerma Sciences2015-06-16Not applicableUs
DermadroxOintment1.356 g/113gTopicalGeritrex Llc2013-01-30Not applicableUs
Dermagran OintmentOintment0.275 %TopicalCanadian Medical Supply Inc.1987-12-311996-09-09Canada
DermaMedOintment2 g/100gTopicalDermarite Industries, Llc2016-10-18Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acid Gone AntacidAluminum hydroxide (95 mg/15mL) + Magnesium carbonate (358 mg/15mL)LiquidOralMajor2004-12-30Not applicableUs
Acid Gone Antacid Extra StrengthAluminum hydroxide (160 mg/1) + Magnesium carbonate (105 mg/1)Tablet, chewableOralMajor2014-06-06Not applicableUs
Acid Gone Antacid Extra StrengthAluminum hydroxide (160 mg/1) + Magnesium carbonate (105 mg/1)Tablet, chewableOralAvera Mc Kennan Hospital2015-07-092018-07-07Us
Acidex Tc Oral SuspensionAluminum hydroxide (600 mg) + Magnesium hydroxide (300 mg)SuspensionOralGen Drug Company Ltd.Not applicable1997-05-30Canada
Advanced Antacid CherryAluminum hydroxide (400 mg/5mL) + Dimethicone (40 mg/5mL) + Magnesium hydroxide (400 mg/5mL)LiquidOralMc Kesson2012-06-01Not applicableUs
Advanced Antacid Regular StrengthAluminum hydroxide (200 mg/5mL) + Dimethicone (20 mg/5mL) + Magnesium hydroxide (200 mg/5mL)LiquidOralSunmark (Mckesson)2012-06-01Not applicableUs
Advanced Regular Strength AntacidAluminum hydroxide (200 mg/5mL) + Dimethicone (20 mg/5mL) + Magnesium hydroxide (200 mg/5mL)SuspensionOralWalgreen2015-01-01Not applicableUs
Alka Phenyl TabAluminum hydroxide (100 mg) + Magnesium Trisilicate (150 mg) + Phenylbutazone (100 mg)TabletOralDuchesnay Inc.1978-12-311997-08-11Canada
Alka Phenylbutazone TabAluminum hydroxide (100 mg) + Magnesium Trisilicate (150 mg) + Phenylbutazone (100 mg)TabletOralPro Doc Limitee1974-12-311997-08-14Canada
AlmaconeAluminum hydroxide (200 mg/5mL) + Magnesium hydroxide (200 mg/5mL)LiquidOralRebel Distributors2008-11-11Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AHC Premium Intense Contour BalmAluminum hydroxide (.45 g/50mL) + Adenosine (.02 g/50mL) + Aluminium tristearate (.04 g/50mL) + Arbutin (1 g/50mL) + Methicone (20 cst) (1.3 g/50mL) + Octinoxate (1.5 g/50mL) + Talc (2.05 g/50mL) + Titanium dioxide (3.96 g/50mL) + Zinc oxide (.96 g/50mL)CreamTopicalCarver Korea Co.,Ltd.2014-01-152017-11-24Us
Medi Hydro DP BB CreamAluminum hydroxide (.07 mg/100mL) + Adenosine (.00004 mg/100mL) + Nicotinamide (.02 mg/100mL) + Stearic acid (.05 mg/100mL) + Titanium dioxide (.05 mg/100mL)CreamTopicalMbg Inc (Korea Institute of Science Development)2016-08-08Not applicableUs
International/Other Brands
AlternaGel (J&J-Merck) / Alu-Cap (3M) / Amphojel (Wyeth)
Categories
UNII
5QB0T2IUN0
CAS number
21645-51-2
Weight
Average: 78.0036
Monoisotopic: 77.989757403
Chemical Formula
AlH3O3
InChI Key
WNROFYMDJYEPJX-UHFFFAOYSA-K
InChI
InChI=1S/Al.3H2O/h;3*1H2/q+3;;;/p-3
IUPAC Name
aluminium(3+) trihydroxide
SMILES
[OH-].[OH-].[OH-].[Al+3]

Pharmacology

Indication

For relief of heartburn and acid indigestion.

Associated Conditions
Pharmacodynamics

Gastric-peptic disease occurs as a result of an imbalance between protective factors, such as mucus, bicarbonate, and prostaglandin secretion, and aggressive factors, such as hydrochloric acid, pepsin, and Helicobacter pylori (H. pylori). Antacids work by restoring acid-base balance, attenuating the pepsin activity and increasing bicarbonate and prostaglandin secretion.

Mechanism of action

Aluminum hydroxide is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Aluminum hydroxide is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.

Absorption

Approximately 17-30% of the aluminum chloride formed is absorbed.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Not metabolized.

Route of elimination

Absorbed aluminum chloride is rapidly eliminated by the kidneys in patients with normal renal function.

Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1alpha-Hydroxyvitamin D5The serum concentration of Aluminum hydroxide can be increased when it is combined with 1alpha-Hydroxyvitamin D5.Investigational
2,5-Dimethoxy-4-ethylamphetamineAluminum hydroxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineAluminum hydroxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Experimental
3,4-MethylenedioxyamphetamineAluminum hydroxide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAluminum hydroxide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
AcepromazineAluminum hydroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineAluminum hydroxide can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetaminophenAluminum hydroxide can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetophenazineAluminum hydroxide can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Aluminum hydroxide.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Aluminum hydroxide.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Aluminum hydroxide.Approved
AlfacalcidolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Alfacalcidol.Approved, Nutraceutical
AlimemazineAluminum hydroxide can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolAluminum hydroxide can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Aluminum hydroxide.Approved
AmphetamineAluminum hydroxide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit, Investigational
Ascorbic acidAscorbic acid can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Nutraceutical
AtazanavirAluminum hydroxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Aluminum hydroxide.Approved, Investigational
BecocalcidiolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Becocalcidiol.Investigational
BenazeprilAluminum hydroxide can cause a decrease in the absorption of Benazepril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
BenazeprilatAluminum hydroxide can cause a decrease in the absorption of Benazeprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BenzphetamineAluminum hydroxide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminum hydroxide.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Aluminum hydroxide.Approved
BL-1020Aluminum hydroxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibAluminum hydroxide can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Aluminum hydroxide.Approved
ButaperazineAluminum hydroxide can cause a decrease in the absorption of Butaperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CalcidiolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Calcipotriol.Approved
CalcitriolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Calcitriol.Approved, Nutraceutical
CaptoprilAluminum hydroxide can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational, Nutraceutical, Vet Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Aluminum hydroxide.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Aluminum hydroxide.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Aluminum hydroxide.Approved
ChloroquineAluminum hydroxide can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlorphentermineAluminum hydroxide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineAluminum hydroxide can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineAluminum hydroxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlortetracyclineAluminum hydroxide can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
CholecalciferolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
Cholic AcidAluminum hydroxide can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
CilazaprilAluminum hydroxide can cause a decrease in the absorption of Cilazapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Aluminum hydroxide.Approved, Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Aluminum hydroxide.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Aluminum hydroxide.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Aluminum hydroxide.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational, Vet Approved
ClomocyclineAluminum hydroxide can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CloprednolThe bioavailability of Cloprednol can be decreased when combined with Aluminum hydroxide.Experimental
CorticotropinThe bioavailability of Corticotropin can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Vet Approved
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Aluminum hydroxide.Approved, Investigational
CortivazolThe bioavailability of Cortivazol can be decreased when combined with Aluminum hydroxide.Investigational
CyamemazineAluminum hydroxide can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CysteamineThe bioavailability of Cysteamine can be decreased when combined with Aluminum hydroxide.Approved, Investigational
Dabigatran etexilateAluminum hydroxide can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DabrafenibAluminum hydroxide can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational, Withdrawn
DasatinibAluminum hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferasiroxThe therapeutic efficacy of Deferasirox can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
DeferiproneAluminum hydroxide can cause a decrease in the absorption of Deferiprone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DeflazacortThe bioavailability of Deflazacort can be decreased when combined with Aluminum hydroxide.Approved, Investigational
DelaprilAluminum hydroxide can cause a decrease in the absorption of Delapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
DelavirdineAluminum hydroxide can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DemeclocyclineAluminum hydroxide can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesonideThe bioavailability of Desonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Aluminum hydroxide.Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Aluminum hydroxide.Vet Approved
DexmethylphenidateAluminum hydroxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
DextroamphetamineAluminum hydroxide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionAluminum hydroxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Aluminum hydroxide.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Withdrawn
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Aluminum hydroxide.Approved
DihydrotachysterolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Dihydrotachysterol.Approved
DixyrazineAluminum hydroxide can cause a decrease in the absorption of Dixyrazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Aluminum hydroxide.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Aluminum hydroxide.Approved
DoxercalciferolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Doxercalciferol.Approved
DoxycyclineAluminum hydroxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EldecalcitolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Eldecalcitol.Investigational
ElocalcitolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Elocalcitol.Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Aluminum hydroxide.Approved
ElvitegravirAluminum hydroxide can cause a decrease in the absorption of Elvitegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EnalaprilAluminum hydroxide can cause a decrease in the absorption of Enalapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
EnalaprilatAluminum hydroxide can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ErgocalciferolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Ergocalciferol.Approved, Nutraceutical
ErlotinibAluminum hydroxide can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EthambutolAluminum hydroxide can cause a decrease in the absorption of Ethambutol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Aluminum hydroxide.Approved
Ferric ammonium citrateAluminum hydroxide can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CarboxymaltoseAluminum hydroxide can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric cationAluminum hydroxide can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric hydroxideAluminum hydroxide can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric oxideAluminum hydroxide can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateAluminum hydroxide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric subsulfateAluminum hydroxide can cause a decrease in the absorption of Ferric subsulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Ferric sulfateAluminum hydroxide can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous bisglycinateAluminum hydroxide can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous chlorideAluminum hydroxide can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferrous fumarateAluminum hydroxide can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous gluconateAluminum hydroxide can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous succinateAluminum hydroxide can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous sulfateAluminum hydroxide can cause a decrease in the absorption of Ferrous sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
FerumoxidesAluminum hydroxide can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxsilAluminum hydroxide can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxytolAluminum hydroxide can cause a decrease in the absorption of Ferumoxytol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FexofenadineAluminum hydroxide can cause a decrease in the absorption of Fexofenadine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FlucloroloneThe bioavailability of Fluclorolone can be decreased when combined with Aluminum hydroxide.Experimental
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Aluminum hydroxide.Approved, Investigational
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational
FluocortinThe bioavailability of Fluocortin can be decreased when combined with Aluminum hydroxide.Experimental
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Aluminum hydroxide.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Aluminum hydroxide.Approved, Investigational
FluperoloneThe bioavailability of Fluperolone can be decreased when combined with Aluminum hydroxide.Experimental
FluphenazineAluminum hydroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Aluminum hydroxide.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Aluminum hydroxide.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Aluminum hydroxide.Approved
FluticasoneThe bioavailability of Fluticasone can be decreased when combined with Aluminum hydroxide.Approved, Experimental, Investigational
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Aluminum hydroxide.Approved
Fluticasone propionateThe bioavailability of Fluticasone propionate can be decreased when combined with Aluminum hydroxide.Approved
FormocortalThe bioavailability of Formocortal can be decreased when combined with Aluminum hydroxide.Experimental
FosinoprilAluminum hydroxide can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FosinoprilatAluminum hydroxide can cause a decrease in the absorption of Fosinoprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
GefitinibAluminum hydroxide can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GepefrineAluminum hydroxide may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GleptoferronAluminum hydroxide can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
HalcinonideThe bioavailability of Halcinonide can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Withdrawn
HalometasoneThe bioavailability of Halometasone can be decreased when combined with Aluminum hydroxide.Experimental
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
Hydrocortisone aceponateThe bioavailability of Hydrocortisone aceponate can be decreased when combined with Aluminum hydroxide.Experimental, Vet Approved
Hydrocortisone acetateThe bioavailability of Hydrocortisone acetate can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
Hydrocortisone butyrateThe bioavailability of Hydrocortisone butyrate can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
Hydrocortisone probutateThe bioavailability of Hydrocortisone probutate can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
Hydrocortisone succinateThe bioavailability of Hydrocortisone succinate can be decreased when combined with Aluminum hydroxide.Approved
Hydrocortisone valerateThe bioavailability of Hydrocortisone valerate can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
HydroxyamphetamineAluminum hydroxide may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HyoscyamineAluminum hydroxide can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
ImidaprilAluminum hydroxide can cause a decrease in the absorption of Imidapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Incadronic acidThe serum concentration of Incadronic acid can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
InecalcitolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Inecalcitol.Experimental, Investigational
Iofetamine I-123Aluminum hydroxide may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IronAluminum hydroxide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranAluminum hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron isomaltoside 1000Aluminum hydroxide can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iron saccharateAluminum hydroxide can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ItraconazoleAluminum hydroxide can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
KetoconazoleAluminum hydroxide can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Aluminum hydroxide.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Aluminum hydroxide.Approved
LedipasvirAluminum hydroxide can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Aluminum hydroxide.Approved
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Aluminum hydroxide.Approved
LisdexamfetamineAluminum hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LisinoprilAluminum hydroxide can cause a decrease in the absorption of Lisinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LoteprednolThe bioavailability of Loteprednol can be decreased when combined with Aluminum hydroxide.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
LymecyclineAluminum hydroxide can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Aluminum hydroxide.Approved
Magnesium hydroxideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
Magnesium oxideThe therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Aluminum hydroxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Aluminum hydroxide.Experimental
Magnesium sulfateThe therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational, Vet Approved
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
MaxacalcitolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Maxacalcitol.Approved, Investigational
MecamylamineAluminum hydroxide may decrease the excretion rate of Mecamylamine which could result in a higher serum level.Approved, Investigational
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Aluminum hydroxide.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Aluminum hydroxide.Vet Approved
MemantineAluminum hydroxide may decrease the excretion rate of Memantine which could result in a higher serum level.Approved, Investigational
MephedroneAluminum hydroxide may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineAluminum hydroxide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MeprednisoneThe bioavailability of Meprednisone can be decreased when combined with Aluminum hydroxide.Approved, Investigational
MequitazineAluminum hydroxide can cause a decrease in the absorption of Mequitazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MesalazineAluminum hydroxide can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MesoridazineAluminum hydroxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethacyclineAluminum hydroxide can cause a decrease in the absorption of Methacycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethamphetamineAluminum hydroxide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Aluminum hydroxide.Approved, Vet Approved
MethotrimeprazineAluminum hydroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethoxyphenamineAluminum hydroxide may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Aluminum hydroxide.Approved
Methylene blueAluminum hydroxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethylphenidateAluminum hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
MidomafetamineAluminum hydroxide may decrease the excretion rate of Midomafetamine which could result in a higher serum level.Experimental, Illicit, Investigational
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Aluminum hydroxide.Approved, Vet Approved
MinocyclineAluminum hydroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe serum concentration of Misoprostol can be decreased when it is combined with Aluminum hydroxide.Approved
MMDAAluminum hydroxide may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MoexiprilAluminum hydroxide can cause a decrease in the absorption of Moexipril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MometasoneThe bioavailability of Mometasone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
Mometasone furoateThe bioavailability of Mometasone furoate can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
MoricizineAluminum hydroxide can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
Mycophenolic acidAluminum hydroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NilotinibAluminum hydroxide can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NitroprussideAluminum hydroxide can cause a decrease in the absorption of Nitroprusside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OmapatrilatAluminum hydroxide can cause a decrease in the absorption of Omapatrilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Aluminum hydroxide.Investigational, Withdrawn
OxytetracyclineAluminum hydroxide can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Aluminum hydroxide.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Aluminum hydroxide.Approved
ParicalcitolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol.Approved, Investigational
PazopanibAluminum hydroxide can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineAluminum hydroxide can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenimepicyclineAluminum hydroxide can cause a decrease in the absorption of Penimepicycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Aluminum hydroxide.Experimental
PerazineAluminum hydroxide can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerflubutaneAluminum hydroxide can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerindoprilAluminum hydroxide can cause a decrease in the absorption of Perindopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PerindoprilatAluminum hydroxide can cause a decrease in the absorption of Perindoprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PerphenazineAluminum hydroxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Aluminum hydroxide.Approved, Withdrawn
PhentermineAluminum hydroxide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Aluminum hydroxide.Approved
PipotiazineAluminum hydroxide can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Aluminum hydroxide.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aluminum hydroxide.Approved, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
Potassium CitratePotassium Citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational, Vet Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Aluminum hydroxide.Approved, Investigational
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
PrednylideneThe bioavailability of Prednylidene can be decreased when combined with Aluminum hydroxide.Experimental
ProchlorperazineAluminum hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineAluminum hydroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineAluminum hydroxide can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropericiazineAluminum hydroxide can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropiopromazineAluminum hydroxide can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Aluminum hydroxide.Approved
Prussian blueAluminum hydroxide can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PseudoephedrineAluminum hydroxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinaprilAluminum hydroxide can cause a decrease in the absorption of Quinapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
QuinaprilatAluminum hydroxide can cause a decrease in the absorption of Quinaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
QuinidineAluminum hydroxide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
QuinineAluminum hydroxide can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Aluminum hydroxide.Approved
RamiprilAluminum hydroxide can cause a decrease in the absorption of Ramipril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RamiprilatAluminum hydroxide can cause a decrease in the absorption of Ramiprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
RescinnamineAluminum hydroxide can cause a decrease in the absorption of Rescinnamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RifampicinAluminum hydroxide can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Aluminum hydroxide.Approved
RiociguatAluminum hydroxide can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
RitobegronAluminum hydroxide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RolitetracyclineAluminum hydroxide can cause a decrease in the absorption of Rolitetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RosuvastatinAluminum hydroxide can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Aluminum hydroxide.Approved
SeocalcitolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Seocalcitol.Experimental, Investigational
Sodium CitrateSodium Citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
Sodium feredetateAluminum hydroxide can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Aluminum hydroxide.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Aluminum hydroxide.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Aluminum hydroxide.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Aluminum hydroxide.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Aluminum hydroxide.Approved
SpiraprilAluminum hydroxide can cause a decrease in the absorption of Spirapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Aluminum hydroxide.Approved, Withdrawn
SulpirideThe therapeutic efficacy of Sulpiride can be increased when used in combination with Aluminum hydroxide.Approved, Investigational
TacalcitolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Tacalcitol.Experimental, Investigational
Technetium Tc-99m oxidronateThe serum concentration of Technetium Tc-99m oxidronate can be increased when it is combined with Aluminum hydroxide.Approved
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational, Withdrawn
TemocaprilAluminum hydroxide can cause a decrease in the absorption of Temocapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
TetracyclineAluminum hydroxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Tetraferric tricitrate decahydrateAluminum hydroxide can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThiazinamAluminum hydroxide can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineAluminum hydroxide can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioproperazineAluminum hydroxide can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThioridazineAluminum hydroxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
TigecyclineAluminum hydroxide can cause a decrease in the absorption of Tigecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Aluminum hydroxide.Approved, Withdrawn
TolevamerThe risk or severity of adverse effects can be increased when Tolevamer is combined with Aluminum hydroxide.Approved, Investigational
TrandolaprilAluminum hydroxide can cause a decrease in the absorption of Trandolapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Aluminum hydroxide.Approved, Vet Approved
TriethylenetetramineAluminum hydroxide can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TrifluoperazineAluminum hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TriflupromazineAluminum hydroxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrilostaneThe bioavailability of Trilostane can be decreased when combined with Aluminum hydroxide.Approved, Investigational, Vet Approved, Withdrawn
UlobetasolThe bioavailability of Ulobetasol can be decreased when combined with Aluminum hydroxide.Approved
Ursodeoxycholic acidThe serum concentration of Ursodeoxycholic acid can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
Vitamin DThe serum concentration of Aluminum hydroxide can be increased when it is combined with Vitamin D.Approved, Nutraceutical, Vet Approved
ZofenoprilAluminum hydroxide can cause a decrease in the absorption of Zofenopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Aluminum hydroxide.Approved
Food Interactions
Not Available

References

Synthesis Reference

Richard H. Goheen, William A. Nigro, Paul J. The, "Process for producing aluminum hydroxide of improved whiteness." U.S. Patent US4915930, issued November, 1933.

US4915930
General References
Not Available
External Links
KEGG Compound
C13391
PubChem Compound
10176082
PubChem Substance
175427087
ChemSpider
8351587
ChEBI
33130
ChEMBL
CHEMBL1200706
Wikipedia
Aluminum_hydroxide
ATC Codes
A02AD03 — AlmagateA02AB01 — Aluminium hydroxideA02AB02 — Algeldrate
AHFS Codes
  • 56:04.00 — Antacids and Adsorbents
  • 84:04.92 — Miscellaneous Local Anti-infectives

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingPreventionExposure to Hepatitis B Virus1
1CompletedBasic ScienceGastroesophageal Reflux Disease1
1CompletedBasic ScienceHealthy Volunteers3
1CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
1CompletedPreventionFlu caused by Influenza1
1CompletedPreventionHIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections1
1CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections6
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentToxic Shock Syndrome Staphylococcal1
1RecruitingBasic ScienceGastroesophageal Reflux Disease1
1RecruitingPreventionHuman Immunodeficiency Virus (HIV) Infections1
1WithdrawnPreventionCoronavirus (SARS-CoV)1
1WithdrawnPreventionHIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections1
1WithdrawnPreventionSevere Acute Respiratory Syndrome1
1, 2CompletedPreventionFlu caused by Influenza3
1, 2RecruitingPreventionH7N9 Influenza1
2CompletedNot AvailableAcid Reflux Disease / Gastro-esophageal Reflux Disease (GERD) / Heartburn / Regurgitation1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
3TerminatedTreatmentRadiation-induced Oesophagitis1
4CompletedTreatmentEmergency / Indigestion / Pain1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedPreventionRenal Failure1
Not AvailableUnknown StatusPreventionPeptic Ulcers / Ulcer Complications1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral600 mg
GelOral320 mg/5mL
LiquidOral320 mg/5mL
OintmentTopical.275 g/100g
OintmentTopical1.356 g/113g
OintmentTopical0.275 %
OintmentTopical2 g/100g
SolutionOral
PowderOral
Tablet, chewableOral
TabletOral
GranuleOral
CreamTopical
LiquidTopical
LiquidOral
SuspensionOral
TabletOral; Other
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP1.45ChemAxon
pKa (Strongest Acidic)4.07ChemAxon
Physiological Charge3ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5922
Blood Brain Barrier+0.8181
Caco-2 permeable-0.5094
P-glycoprotein substrateNon-substrate0.8274
P-glycoprotein inhibitor INon-inhibitor0.9892
P-glycoprotein inhibitor IINon-inhibitor0.9783
Renal organic cation transporterNon-inhibitor0.9433
CYP450 2C9 substrateNon-substrate0.8282
CYP450 2D6 substrateNon-substrate0.9
CYP450 3A4 substrateNon-substrate0.8206
CYP450 1A2 substrateNon-inhibitor0.9291
CYP450 2C9 inhibitorNon-inhibitor0.9148
CYP450 2D6 inhibitorNon-inhibitor0.9584
CYP450 2C19 inhibitorNon-inhibitor0.9447
CYP450 3A4 inhibitorNon-inhibitor0.9672
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9578
Ames testNon AMES toxic0.8393
CarcinogenicityCarcinogens 0.5918
BiodegradationReady biodegradable0.81
Rat acute toxicity1.7247 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9592
hERG inhibition (predictor II)Non-inhibitor0.9742
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as post-transition metal hydroxides. These are inorganic compounds in which the largest oxoanion is hydroxide, and in which the heaviest atom not in an oxoanion is a post-transition metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Post-transition metal oxoanionic compounds
Sub Class
Post-transition metal hydroxides
Direct Parent
Post-transition metal hydroxides
Alternative Parents
Post-transition metal salts / Inorganic salts / Inorganic oxides / Inorganic hydrides
Substituents
Post-transition metal hydroxide / Inorganic post-transition metal salt / Inorganic hydride / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
aluminium hydroxides (CHEBI:33130)

Drug created on August 09, 2010 11:11 / Updated on August 15, 2018 09:54